{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:33:15Z","timestamp":1791862395979,"version":"4.3.4"},"reference-count":164,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011925","name":"ESHRE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>STUDY QUESTION<\/jats:title>\n                    <jats:p>What is the recommended management of ovarian stimulation, based on the best available evidence in the literature?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY ANSWER<\/jats:title>\n                    <jats:p>This updated ESHRE guideline on ovarian stimulation for IVF\/ICSI provides 121 recommendations, answering 21\u2009key questions on ovarian stimulation for IVF\/ICSI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WHAT IS KNOWN ALREADY?<\/jats:title>\n                    <jats:p>Before the ESHRE guideline on ovarian stimulation for IVF\/ICSI was published in 2019, ovarian stimulation for IVF\/ICSI had only been discussed briefly in the National Institute for Health and Care Excellence guideline on fertility problems and in a statement by the Royal Australian and New Zealand College of Obstetricians and Gynaecologists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                    <jats:p>The guideline was developed according to the structured methodology for ESHRE guidelines. The 18\u2009key questions from the 2019 version of the guideline were revised by the Guideline Development Group (GDG). This resulted in the addition of one new key question, the splitting of the key question on fertility preservation in three separate key questions (fertility preservation for women facing gonadotoxic treatment, elective oocyte cryopreservation, and oocyte donation) and several new interventions being added to the existing key questions. Papers published between 31 October 2018 and 2 February 2025 and written in English were included. The critical outcomes for this guideline were efficacy in terms of cumulative live birth rate per started cycle or live birth rate per started cycle, as well as safety in terms of the rate of occurrence of moderate and\/or severe ovarian hyperstimulation syndrome (OHSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                    <jats:p>Based on the available evidence, recommendations were formulated and discussed until consensus was reached within the GDG. Following stakeholder review of the initial draft, the final version was approved by the GDG and ultimately by the ESHRE Executive Committee.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                    <jats:p>The guideline provides a total of 121 recommendations: 42 recommendations remained unchanged in 2019, 4 recommendations were reworded for better understanding, 29 recommendations were updated in view of new evidence, and 46 new recommendations for 2025 have been formulated. The guideline provides 4 recommendations on pre-stimulation evaluation, 7 recommendations on pre-treatment therapies, 50 recommendations on pituitary suppression and ovarian stimulation, 17 recommendations on monitoring, 18 recommendations on triggering of final oocyte maturation and luteal support, and 8 recommendations on the prevention of OHSS. In addition, the guideline provides 17 recommendations on fertility preservation, both oncologic and elective, and oocyte donation. These include 90 evidence-based recommendations, of which only 42 were formulated as strong recommendations and 48 as conditional, as well as 29 good practice points and 2 research-only recommendations. Of the evidence-based recommendations, none were supported by high-quality evidence, 6 by moderate-quality evidence, 36 by low-quality evidence, and 148 by very low-quality evidence. To support future research on ovarian stimulation for IVF\/ICSI, a list of research recommendations was provided.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                    <jats:p>Several newer interventions are not well studied yet. For most of these interventions, a recommendation against the intervention or a research-only recommendation was formulated based on insufficient evidence. Future studies may require these recommendations to be revised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                    <jats:p>The guideline provides clinicians with clear advice on best practice in ovarian stimulation, based on the best evidence available. In addition, a list of research recommendations is provided to promote further studies in ovarian stimulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                    <jats:p>The guideline was developed by ESHRE, who funded the guideline meetings, literature searches, and dissemination of the guideline. The guideline group members did not receive any financial incentives; all work was provided voluntarily. BA reports speaker\u2019s fees from Gedeon-Richter, Ferring, IBSA, Intas, Merck, Organon, consulting fees from Merck, Organon, Oxolife, stock options from Global Fertility Solutions LLC (employee co-investment), and was chair of the Turkish Society of Reproductive Medicine. EB reports research grants from Roche Diagnostics and IBSA, consulting fees from MSD, Abbot, Gedeon-Richter, Roche, speaker\u2019s fees from IBSA, MSD, Ferring Pharmaceuticals, Abbot, Gedeon-Richter, Merck, Roche, participation in the advisory board of Ferring Pharmaceuticals, IBSA and Merck, and ownership interest from IVI-RMS Valencia. GG was part of the ESHRE working group on Recurrent Implantation Failure and the ESHRE working group on clinical KPISs, reports travel support from Merck, Organon, Ferring, Theramex, Gedeon-Richter, Abbott, consulting fees from Organon, Ferring, Merck, Gedeon-Richter, Theramex, Abbott, ReproNovo, Igyxos, OxoLife, Philipps, ReprodWissen, PregLem, Guerbet, Roche, IBSA, and Besins, speaker\u2019s fees from Organon, Ferring, Merck, Gedeon-Richter, Theramex, Abbott, ReproNovo, Igyxos, OxoLife, Philipps, ReprodWissen, PregLem, Guerbet, Roche, IBSA, and Besins, and research grants from Besin, Merck, Abbott, Ferring, Theramex. MG reports speaker\u2019s fees from Merck Serono, Ferring, and Gedeon Richter. EK reports travel\/hotel expenses from Ferring, Merck SERONO, Vianex, speaker\u2019s fees from Ferring, Merck SERONO, Vianex, and is chair of the Greek Society of Fertility and Sterility. MK reports travel support and speaker\u2019s fees from Ferring. ALM reports research grants from Merck, Ferring, IBSA, Roche, Organon, Theramex, Beckman Coulter, and Gedeon-Richter, consulting fees from Merck, Ferring, IBSA, Roche, Organon, Theramex, Beckman Coulter, and Gedeon-Richter, speaker\u2019s fees from Merck, Ferring, IBSA, Roche, Organon, Theramex, Beckman Coulter, Gedeon-Richter, and participation on an advisory board of Merck, Organon, Ferring, Theramex, Gedeon Richter, and IBSA. GL reports consulting fees from Ferring and Merck, speaker\u2019s fees from Ferring, Merck, Gedeon-Richter, Organon, and Vianex, expert testimony fees from Cook, travel support from ESHRE, Ferring, Merck, Gedeon-Richter, Organon, and Vianex, is on the advisory board of Merck and Ferring, and participated in an ESHRE committee and on the Greek Fertility and Sterility Committee. NM reports research grants from IBSA, Organon, consulting fees from Organon, Merck, GE, Ferring, Abbott, and Cooper, and speaker\u2019s fees from Ferring, GE, Organon, IBSA, Merck, Theramex. NPP reports research grants from Besins Healthcare, Ferring Pharmaceutical, Merck Serono, Organon, Roche Diagnostics, and Theramex, consulting fees from Besins Healthcare, Alife, Ferring, IBSA, Merck Serono, Organon, Abbott, FertilAI, and speaker\u2019s fees from Besins Healthcare, Roche Diagnostics, Ferring Pharmaceuticals, Gedeon-Richter, IBSA, Merck Serono, Organon, and Theramex. SKS reports a research grant from Ferring, travel support from Merck and INTAS, consulting fees from Merck, and speaker\u2019s fees from Merck, MSD, INTAS, and Ferring. TT reports travel support from Merck, speaker\u2019s fees from Merck, Organon, MSD and is editor-in-chief of a Bulgarian journal, Reproductive Health. MT reports travel support from IBSA, Ferring, and Merck, consulting fees from Abbott and is a member of the board of the Finnish Endocrine Society. JU is a member of the Steering Committee of Richter Reproduction Network and received travel support from IBSA. FB reports a research grant from Besins, is on the advisory board of Merck and Abbott, reports speaker\u2019s fees from Ferring, Merck, Besins, Intas Fermaceuticals, PREIS School; he is the owner of FRANKSCHOOL RforL. The other authors have nothing to disclose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                    <jats:p>N\/A.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCLAIMER<\/jats:title>\n                    <jats:p>This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained.<\/jats:p>\n                    <jats:p>Adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not replace the need for application of clinical judgment to each individual presentation, nor variations based on locality and facility type.<\/jats:p>\n                    <jats:p>ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. (The full disclaimer is available at www.eshre.eu\/guidelines.)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humrep\/deag018","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:39:40Z","timestamp":1769603980000},"source":"Crossref","is-referenced-by-count":11,"title":["ESHRE guideline: ovarian stimulation for IVF\/ICSI: an update in 2025"],"prefix":"10.1093","author":[{"name":"The ESHRE Guideline Group on Ovarian Stimulation","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-3747","authenticated-orcid":false,"given":"B","family":"Ata","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Koc University , Istanbul,","place":["Turkey"]},{"name":"ART Fertility Clinics , Dubai,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-5931","authenticated-orcid":false,"given":"E","family":"Bosch","sequence":"additional","affiliation":[{"name":"IVI-RMS Valencia , Valencia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Broer","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine and Gynecology, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0606-5804","authenticated-orcid":false,"given":"G","family":"Griesinger","sequence":"additional","affiliation":[{"name":"Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital Schleswig-Holstein , L\u00fcbeck,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1549-1802","authenticated-orcid":false,"given":"M","family":"Grynberg","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine and Fertility Preservation, Hospital Jean Verdier , Bondy,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-9460","authenticated-orcid":false,"given":"E","family":"Kolibianakis","sequence":"additional","affiliation":[{"name":"Unit for Human Reproduction, 1st Department of ObGyn, Medical School, Aristotle University , Thessaloniki,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Kunicki","sequence":"additional","affiliation":[{"name":"INVICTA Fertility and Reproductive Centre , Warsaw,","place":["Poland"]},{"name":"Department of Gynaecological Endocrinology, Medical University of Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-9547","authenticated-orcid":false,"given":"A","family":"La Marca","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia , Modena,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3865-7142","authenticated-orcid":false,"given":"G","family":"Lainas","sequence":"additional","affiliation":[{"name":"Eugonia IVF, Unit of Human Reproduction , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4574-1809","authenticated-orcid":false,"given":"N","family":"Le Clef","sequence":"additional","affiliation":[{"name":"European Society of Human Reproduction and Embryology ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0055-2377","authenticated-orcid":false,"given":"N","family":"Massin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynaecology and Reproduction, University Paris-Est Cr\u00e9teil, Centre Hospitalier Intercommunal , Cr\u00e9teil,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6161-0011","authenticated-orcid":false,"given":"N P","family":"Polyzos","sequence":"additional","affiliation":[{"name":"Dexeus University Hospital , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1530-4854","authenticated-orcid":false,"given":"S K","family":"Sunkara","sequence":"additional","affiliation":[{"name":"Department of Women and Children\u2019s Health, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4042-4038","authenticated-orcid":false,"given":"T","family":"Timeva","sequence":"additional","affiliation":[{"name":"IVF Department, Specialized Obstetrics and Gynecology Hospital \u201cDr. Shterev\u201d , Sofia,","place":["Bulgaria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"T\u00f6yli","sequence":"additional","affiliation":[{"name":"Kanta-H\u00e4me Central Hospital, H\u00e4meenlinna, Mehil\u00e4inen Clinics , Helsinki,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Urbancsek","sequence":"additional","affiliation":[{"name":"Division of Assisted Reproduction, Department of Obstetrics and Gynaecology, Semmelweis University Faculty of Medicine , Budapest,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1366-2727","authenticated-orcid":false,"given":"F","family":"Broekmans","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine and Gynecology, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]},{"name":"Centre for Childwish, Dijklander Hospital , Purmerend,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"2026022403013837700_deag018-B1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000010143","article-title":"Luteal phase support with 17alpha-hydroxyprogesterone versus unsupported cycles in in vitro fertilization: a comparative randomized study","volume":"48","author":"Abate","year":"1999","journal-title":"Gynecol Obstet Invest"},{"key":"2026022403013837700_deag018-B2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S1472-6483(10)61098-X","article-title":"Increasing the dose of human menopausal gonadotrophins on day of GnRH antagonist administration: randomized controlled trial","volume":"8","author":"Aboulghar","year":"2004","journal-title":"Reprod Biomed Online"},{"key":"2026022403013837700_deag018-B3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1023\/A:1009470602525","article-title":"Reduction of human menopausal gonadotropin dose before coasting prevents severe ovarian hyperstimulation syndrome with minimal cycle cancellation","volume":"17","author":"Aboulghar","year":"2000","journal-title":"J Assist Reprod Genet"},{"key":"2026022403013837700_deag018-B4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.fertnstert.2004.03.020","article-title":"Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles","volume":"82","author":"Acevedo","year":"2004","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.29252\/ijrm.16.1.9","article-title":"Fresh versus frozen embryo transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone antagonist cycles among high responder women: a randomized, multi-center study","volume":"16","author":"Aflatoonian","year":"2018","journal-title":"IJRM"},{"key":"2026022403013837700_deag018-B6","doi-asserted-by":"crossref","first-page":"1239175","DOI":"10.3389\/frph.2023.1239175","article-title":"Conventional ovarian stimulation vs. delayed single dose corifollitropin alfa ovarian stimulation in oocyte donors: a prospective randomized study. Tail trial","volume":"5","author":"Alvarado Franco","year":"2023","journal-title":"Front Reprod Health"},{"key":"2026022403013837700_deag018-B7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2026022403013837700_deag018-B8","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.fertnstert.2014.08.013","article-title":"Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antiM\u00fcllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization\/intracytoplasmic sperm injection","volume":"102","author":"Arce","year":"2014","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.mefs.2015.12.004","article-title":"Adjuvant sildenafil therapy in poor responders undergoing in vitro fertilization: a prospective, randomized, double-blind, placebo-controlled trial","volume":"21","author":"Ataalla","year":"2016","journal-title":"Middle East Fertil Soc J"},{"key":"2026022403013837700_deag018-B10","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/humrep\/del484","article-title":"Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial","volume":"22","author":"Baart","year":"2007","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B11","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/humrep\/dei475","article-title":"Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial","volume":"21","author":"Babayof","year":"2006","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B12","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.fertnstert.2024.11.011","article-title":"Triggering oocyte maturation in in vitro fertilization treatment in healthy responders: a systematic review and network meta-analysis","volume":"123","author":"Beebeejaun","year":"2025","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1477-7827-7-91","article-title":"hCG priming\u201d effect in controlled ovarian stimulation through a long protocol","volume":"7","author":"Beretsos","year":"2009","journal-title":"Reprod Biol Endocrinol"},{"key":"2026022403013837700_deag018-B14","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.fertnstert.2011.01.028","article-title":"Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization\/intracytoplasmic sperm injection treatment cycle: impact on ovarian stimulation. A pilot study","volume":"95","author":"Blockeel","year":"2011","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B15","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1210\/jc.2010-2239","article-title":"Follicular phase endocrine characteristics during ovarian stimulation and GnRH antagonist cotreatment for IVF: RCT comparing recFSH initiated on cycle day 2 or 5","volume":"96","author":"Blockeel","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026022403013837700_deag018-B16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.fertnstert.2010.06.068","article-title":"Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis","volume":"95","author":"Bodri","year":"2011","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B17","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s10815-016-0721-5","article-title":"Ovarian stimulation in the luteal phase: systematic review and meta-analysis","volume":"33","author":"Boots","year":"2016","journal-title":"J Assist Reprod Genet"},{"key":"2026022403013837700_deag018-B18","doi-asserted-by":"crossref","first-page":"hoz008","DOI":"10.1093\/hropen\/hoz008","article-title":"Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis","volume":"2019","author":"Bordewijk","year":"2019","journal-title":"Hum Reprod Open"},{"key":"2026022403013837700_deag018-B19","first-page":"8","article-title":"Strategies for the management of OHSS: Results from freezing-all cycles","volume":"20","author":"Borges","year":"2016","journal-title":"JBRA Assist Reprod"},{"key":"2026022403013837700_deag018-B20","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/humrep\/dead276","article-title":"Does dual oocyte retrieval with continuous FSH administration increase the number of mature oocytes in low responders? An open-label randomized controlled trial","volume":"39","author":"Boudry","year":"2024","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/humupd\/dml034","article-title":"A systematic review of tests predicting ovarian reserve and IVF outcome","volume":"12","author":"Broekmans","year":"2006","journal-title":"Hum Reprod Update"},{"key":"2026022403013837700_deag018-B22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.fertnstert.2013.04.024","article-title":"Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis","volume":"100","author":"Broer","year":"2013","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/humupd\/dms041","article-title":"Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach","volume":"19","author":"Broer","year":"2013","journal-title":"Hum Reprod Update"},{"key":"2026022403013837700_deag018-B24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/humrep\/deab249","article-title":"Impact of letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF: a multicentre, randomized, double-blinded placebo-controlled trial","volume":"37","author":"B\u00fclow","year":"2022","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B25","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s10815-012-9863-2","article-title":"MILD ovarian stimulation with GnRH-antagonist vs. long protocol with low dose FSH for non-PCO high responders undergoing IVF: a prospective, randomized study including thawing cycles","volume":"29","author":"Casano","year":"2012","journal-title":"J Assist Reprod Genet"},{"key":"2026022403013837700_deag018-B26","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0015-0282(00)00471-4","article-title":"A comparative study of high fixed-dose and decremental-dose regimens of gonadotropins in a minidose gonadotropin-releasing hormone agonist flare protocol for poor responders","volume":"73","author":"Cedrin-Durnerin","year":"2000","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B27","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.rbmo.2022.11.012","article-title":"A randomized, non-inferiority trial on the DuoStim strategy in PGT-A cycles","volume":"46","author":"Cerrillo","year":"2023","journal-title":"Reprod Biomed Online"},{"key":"2026022403013837700_deag018-B28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.rbmo.2021.08.003","article-title":"Fertility preservation for women with breast cancer before chemotherapy: a systematic review and meta-analysis","volume":"44","author":"Chen","year":"2022","journal-title":"Reprod Biomed Online"},{"key":"2026022403013837700_deag018-B29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3109\/09513590.2014.895984","article-title":"Timing of human chorionic gonadotropin (hCG) hormone administration in IVF\/ICSI protocols using GnRH agonist or antagonists: a systematic review and meta-analysis","volume":"30","author":"Chen","year":"2014","journal-title":"Gynecol Endocrinol"},{"key":"2026022403013837700_deag018-B30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12958-021-00759-4","article-title":"Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Conforti","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"key":"2026022403013837700_deag018-B31","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.fertnstert.2018.11.047","article-title":"Corifollitropin alfa for ovarian stimulation in in vitro fertilization: a systematic review and meta-analysis of randomized controlled trials","volume":"111","author":"Cozzolino","year":"2019","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.rbmo.2017.03.003","article-title":"Economic impact of ovarian stimulation with corifollitropin alfa versus conventional daily gonadotropins in oocyte donors: a randomized study","volume":"34","author":"Cruz","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2026022403013837700_deag018-B33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40834-024-00265-z","article-title":"Comparison of luteal phase stimulation with follicular phase stimulation in poor ovarian response: a single-blinded randomized controlled trial","volume":"9","author":"Dastjerdi","year":"2024","journal-title":"Contracept Reprod Med"},{"key":"2026022403013837700_deag018-B34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/humupd\/dmaa035","article-title":"Mild versus conventional ovarian stimulation for IVF in poor, normal and hyper-responders: a systematic review and meta-analysis","volume":"27","author":"Datta","year":"2021","journal-title":"Hum Reprod Update"},{"key":"2026022403013837700_deag018-B35","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s43032-020-00455-5","article-title":"Natural cycle results in lower implantation failure than ovarian stimulation in advanced-age poor responders undergoing IVF: Fertility Outcomes from 585 Patients","volume":"28","author":"De Marco","year":"2021","journal-title":"Reprod Sci"},{"key":"2026022403013837700_deag018-B36","doi-asserted-by":"crossref","first-page":"103889","DOI":"10.1016\/j.rbmo.2024.103889","article-title":"Early versus late follicular phase ovarian stimulation: a randomized controlled trial","volume":"49","author":"De Rijdt","year":"2024","journal-title":"Reprod Biomed Online"},{"key":"2026022403013837700_deag018-B37","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.rbmo.2019.10.008","article-title":"Replacing HMG\/FSH by low-dose HCG to complete corifollitropin alfa stimulation reduces cost per clinical pregnancy: a randomized pragmatic trial","volume":"40","author":"Decleer","year":"2020","journal-title":"Reprod Biomed Online"},{"key":"2026022403013837700_deag018-B38","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.fertnstert.2009.10.034","article-title":"Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting","volume":"94","author":"DiLuigi","year":"2010","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.rbmo.2009.12.019","article-title":"LH concentrations do not correlate with pregnancy in rFSH\/GnRH antagonist cycles","volume":"20","author":"Doody","year":"2010","journal-title":"Reprod Biomed Online"},{"key":"2026022403013837700_deag018-B40","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/oxfordjournals.humrep.a138266","article-title":"Different follicle stimulating hormone\/luteinizing hormone ratios for ovarian stimulation","volume":"8","author":"Duijkers","year":"1993","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B41","first-page":"238","article-title":"Evaluation of pretreatment with Cetrotide in an antagonist protocol for patients with PCOS undergoing IVF\/ICSI cycles: a randomized clinical trial","volume":"22","author":"Eftekhar","year":"2018","journal-title":"JBRA Assist Reprod"},{"key":"2026022403013837700_deag018-B42","first-page":"287","article-title":"Effect of adding letrozole to gonadotropin on in vitro fertilization outcomes: an RCT","volume":"18","author":"Eftekhar","year":"2020","journal-title":"Int J Reprod Biomed"},{"key":"2026022403013837700_deag018-B43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.fertnstert.2007.02.002","article-title":"The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study","volume":"89","author":"Engmann","year":"2008","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B44","first-page":"Cd006109","article-title":"Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques","volume":"5","author":"Farquhar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B45","doi-asserted-by":"crossref","first-page":"926172","DOI":"10.1155\/2014\/926172","article-title":"LH pretreatment as a novel strategy for poor responders","volume":"2014","author":"Ferraretti","year":"2014","journal-title":"Biomed Res Int"},{"key":"2026022403013837700_deag018-B46","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/humrep\/deae041","article-title":"Risk factors for poor oocyte yield and oocyte immaturity after GnRH agonist triggering","volume":"39","author":"Gambini","year":"2024","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B47","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.rbmo.2019.09.005","article-title":"Endometrial thickness and IVF cycle outcomes: a meta-analysis","volume":"40","author":"Gao","year":"2020","journal-title":"Reprod Biomed Online"},{"key":"2026022403013837700_deag018-B48","first-page":"386","article-title":"Evaluation of the effect of letrozole in the ovarian hyperstimulation syndrome prevention in participants at risk of treatment with ovulation-stimulating drugs: a randomized controlled trial","volume":"11","author":"Ghasemi Tehrani","year":"2022","journal-title":"Rep Biochem Mol Biol"},{"key":"2026022403013837700_deag018-B49","first-page":"CD013827","article-title":"Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle","volume":"11","author":"Glujovsky","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"2026022403013837700_deag018-B50","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/oxfordjournals.humrep.a138764","article-title":"Ultrasonic control without hormone determination for ovulation induction in in-vitro fertilization\/embryo transfer with gonadotrophin-releasing hormone analogue and human menopausal gonadotrophin","volume":"9","author":"Golan","year":"1994","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B51","doi-asserted-by":"crossref","first-page":"18769","DOI":"10.1038\/s41598-020-75107-4","article-title":"Growth hormone alleviates oxidative stress and improves oocyte quality in Chinese women with polycystic ovary syndrome: a randomized controlled trial","volume":"10","author":"Gong","year":"2020","journal-title":"Sci Rep"},{"key":"2026022403013837700_deag018-B52","doi-asserted-by":"crossref","first-page":"e0241044","DOI":"10.1371\/journal.pone.0241044","article-title":"Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis","volume":"15","author":"Griesinger","year":"2020","journal-title":"PLoS One"},{"key":"2026022403013837700_deag018-B53","doi-asserted-by":"crossref","first-page":"e0149615","DOI":"10.1371\/journal.pone.0149615","article-title":"Prediction of ovarian hyperstimulation syndrome in patients treated with corifollitropin alfa or rFSH in a GnRH antagonist protocol","volume":"11","author":"Griesinger","year":"2016","journal-title":"PLoS One"},{"key":"2026022403013837700_deag018-B54","doi-asserted-by":"crossref","first-page":"103572","DOI":"10.1016\/j.rbmo.2023.103572","article-title":"Random-start ovarian stimulation in an oocyte donation programme: a large, single-centre, experience","volume":"48","author":"Guerrero","year":"2024","journal-title":"Reprod Biomed Online"},{"key":"2026022403013837700_deag018-B55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejogrb.2023.08.014","article-title":"Triggering of ovulation for GnRH-antagonist cycles in normal and low ovarian responders undergoing IVF\/ICSI: A systematic review and meta-analysis of randomized trials","volume":"289","author":"He","year":"2023","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2026022403013837700_deag018-B56","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12884-022-04499-0","article-title":"Effect of GnRH agonist alone or combined with different low-dose hCG on cumulative live birth rate for high responders in GnRH antagonist cycles: a retrospective study","volume":"22","author":"He","year":"2022","journal-title":"BMC Pregnancy Childbirth"},{"key":"2026022403013837700_deag018-B57","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.fertnstert.2010.09.040","article-title":"Avoiding the use of human chorionic gonadotropin combined with oocyte vitrification and GnRH agonist triggering versus coasting: a new strategy to avoid ovarian hyperstimulation syndrome","volume":"95","author":"Herrero","year":"2011","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B58","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1007\/s43032-021-00622-2","article-title":"Gonadotropin-releasing hormone agonist versus recombinant human chorionic gonadotropin triggering in fertility preservation cycles","volume":"28","author":"Herzberger","year":"2021","journal-title":"Reprod Sci"},{"key":"2026022403013837700_deag018-B59","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1210\/jc.2002-020788","article-title":"A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol","volume":"88","author":"Hohmann","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2026022403013837700_deag018-B60","doi-asserted-by":"crossref","first-page":"e12440","DOI":"10.1002\/rmb2.12440","article-title":"Clinical efficacy of dual trigger with human chorionic gonadotropin and a gonadotropin-releasing hormone agonist for women undergoing fertility preservation","volume":"21","author":"Hong","year":"2022","journal-title":"Reprod Med Biol"},{"key":"2026022403013837700_deag018-B61","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13048-024-01581-3","article-title":"Administration of dehydroepiandrosterone improves endometrial thickness in women undergoing IVF\/ICSI: a systematic review and meta-analysis","volume":"18","author":"Huang","year":"2025","journal-title":"J Ovarian Res"},{"key":"2026022403013837700_deag018-B62","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/humrep\/dex208","article-title":"Efficacy and safety of follitropin alfa\/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders","volume":"32","author":"Humaidan","year":"2017","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B63","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1093\/humrep\/det249","article-title":"GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients","volume":"28","author":"Humaidan","year":"2013","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B64","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0015-0282(16)58572-0","article-title":"Luteal support with both estradiol and progesterone after clomiphene citrate stimulation for in vitro fertilization","volume":"66","author":"Hurd","year":"1996","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B65","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.fertnstert.2020.10.059","article-title":"Randomized, assessor-blind, antiM\u00fcllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization\/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta","volume":"115","author":"Ishihara","year":"2021","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B66","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1472-6483(10)60400-2","article-title":"Randomized controlled pilot trial of luteal phase recombinant FSH stimulation in poor responders","volume":"17","author":"Kansal Kalra","year":"2008","journal-title":"Reprod Biomed Online"},{"key":"2026022403013837700_deag018-B67","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s10815-020-01829-z","article-title":"Is the probability of pregnancy after ovarian stimulation for IVF associated with serum estradiol levels on the day of triggering final oocyte maturation with hCG? A systematic review and meta-analysis","volume":"37","author":"Karatasiou","year":"2020","journal-title":"J Assist Reprod Genet"},{"key":"2026022403013837700_deag018-B68","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/humupd\/dmu011","article-title":"Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis","volume":"20","author":"Kasius","year":"2014","journal-title":"Hum Reprod Update"},{"key":"2026022403013837700_deag018-B69","doi-asserted-by":"crossref","first-page":"102633","DOI":"10.1016\/j.jogoh.2023.102633","article-title":"Cycle outcomes of dual trigger (GnRH agonist+hCG) versus human chorionic gonadotropin trigger alone in POSEDION group 3-4 poor-responders and normo-responders: A prospective randomized study","volume":"52","author":"Keskin","year":"2023","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2026022403013837700_deag018-B70","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.fertnstert.2009.06.005","article-title":"Minimal stimulation using gonadotropin-releasing hormone (GnRH) antagonist and recombinant human follicle-stimulating hormone versus GnRH antagonist multiple-dose protocol in low responders undergoing in vitro fertilization\/intracytoplasmic sperm injection","volume":"92","author":"Kim","year":"2009","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B71","doi-asserted-by":"crossref","first-page":"306","DOI":"10.5653\/cerm.2020.03657","article-title":"Effect of a dual trigger on oocyte maturation in young women with decreased ovarian reserve for the purpose of elective oocyte cryopreservation","volume":"47","author":"Kim","year":"2020","journal-title":"Clin Exp Reprod Med"},{"key":"2026022403013837700_deag018-B72","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10815-006-9036-2","article-title":"Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol","volume":"23","author":"Koichi","year":"2006","journal-title":"J Assist Reprod Genet"},{"key":"2026022403013837700_deag018-B73","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.fertnstert.2006.12.058","article-title":"Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone","volume":"88","author":"Kolibianakis","year":"2007","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B74","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1447-0756.2008.00750.x","article-title":"Efficiency of follicle-stimulating hormone, commenced in the luteal phase, for overcoming a poor response in assisted reproduction","volume":"34","author":"Kucuk","year":"2008","journal-title":"J Obstet Gynaecol Res"},{"key":"2026022403013837700_deag018-B75","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/humrep\/des361","article-title":"Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger","volume":"28","author":"Kummer","year":"2013","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B76","first-page":"Cd005289","article-title":"Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)","volume":"4","author":"Kwan","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B77","doi-asserted-by":"crossref","first-page":"661707","DOI":"10.3389\/fendo.2021.661707","article-title":"Step-down of FSH- dosage during ovarian stimulation - basic lessons to be learnt from a randomized controlled trial","volume":"12","author":"Lawrenz","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026022403013837700_deag018-B78","doi-asserted-by":"crossref","first-page":"30826","DOI":"10.1038\/s41598-024-81539-z","article-title":"Progesterone level in assisted reproductive technology: a systematic review and meta-analysis","volume":"14","author":"Lim","year":"2024","journal-title":"Sci Rep"},{"key":"2026022403013837700_deag018-B79","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1017\/erm.2023.25","article-title":"Live birth rate of gonadotropin-releasing hormone antagonist versus luteal phase gonadotropin-releasing hormone agonist protocol in IVF\/ICSI: a systematic review and meta-analysis","volume":"26","author":"Liu","year":"2023","journal-title":"Expert Rev Mol Med"},{"key":"2026022403013837700_deag018-B80","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s10815-025-03389-6","article-title":"Growth hormone improves the pregnancy outcomes in poor ovarian responders undergoing in vitro fertilization: an umbrella review","volume":"42","author":"Liu","year":"2025","journal-title":"J Assist Reprod Genet"},{"key":"2026022403013837700_deag018-B81","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13048-023-01202-5","article-title":"Comparison of anti-M\u00fcllerian hormone and antral follicle count in the prediction of ovarian response: a systematic review and meta-analysis","volume":"16","author":"Liu","year":"2023","journal-title":"J Ovarian Res"},{"key":"2026022403013837700_deag018-B82","doi-asserted-by":"crossref","first-page":"802688","DOI":"10.3389\/fendo.2022.802688","article-title":"Single-dose versus multiple-dose GnRH agonist for luteal-phase support in women undergoing IVF\/ICSI cycles: a network meta-analysis of randomized controlled trials","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026022403013837700_deag018-B83","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1186\/s12884-023-05944-4","article-title":"Effect of basal luteinizing hormone (bLH) level on in vitro fertilization\/intra-cytoplasmic injections (IVF\/ICSI) outcomes in polycystic ovarian syndrome (PCOS) patients","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"key":"2026022403013837700_deag018-B84","first-page":"4568","article-title":"Gonadotropins- letrozole, gonadotropin- clomiphene citrate, and gonadotropins only for controlled ovarian super stimulation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection","volume":"13","author":"Lotfy","year":"2022","journal-title":"J Pharm Negat Results"},{"key":"2026022403013837700_deag018-B85","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1177\/147323001003800622","article-title":"Modified natural cycle for in vitro fertilization and embryo transfer in normal ovarian responders","volume":"38","author":"Lou","year":"2010","journal-title":"J Int Med Res"},{"key":"2026022403013837700_deag018-B86","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.fertnstert.2016.07.1068","article-title":"Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist","volume":"106","author":"Lu","year":"2016","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B87","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13048-023-01110-8","article-title":"LH level on ovulation trigger day has a different impact on the outcomes of agonist and antagonist regimens during in vitro fertilization","volume":"16","author":"Luo","year":"2023","journal-title":"J Ovarian Res"},{"key":"2026022403013837700_deag018-B88","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10815-012-9919-3","article-title":"Comparing the efficacy of urinary and recombinant hCG on oocyte\/follicle ratio to trigger ovulation in women undergoing intracytoplasmic sperm injection cycles: a randomized controlled trial","volume":"30","author":"Madani","year":"2013","journal-title":"J Assist Reprod Genet"},{"key":"2026022403013837700_deag018-B89","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s10815-012-9854-3","article-title":"Efficacy of low dose hCG on oocyte maturity for ovarian stimulation in poor responder women undergoing intracytoplasmic sperm injection cycle: a randomized controlled trial","volume":"29","author":"Madani","year":"2012","journal-title":"J Assist Reprod Genet"},{"key":"2026022403013837700_deag018-B90","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1472-6483(10)60654-2","article-title":"Impact of duration and dose of gonadotrophins on IVF outcomes","volume":"13","author":"Martin","year":"2006","journal-title":"Reprod Biomed Online"},{"key":"2026022403013837700_deag018-B91","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1093\/humrep\/deac222","article-title":"Comparison of blastocyst euploidy rates following luteal versus follicular phase stimulation in a GnRH antagonist protocol: a prospective study with repeated ovarian stimulation cycles","volume":"37","author":"Martinez","year":"2022","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B92","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/humupd\/dmab008","article-title":"Ovarian stimulation for oocyte donation: a systematic review and meta-analysis","volume":"27","author":"Martinez","year":"2021","journal-title":"Hum Reprod Update"},{"key":"2026022403013837700_deag018-B93","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/humrep\/deaa042","article-title":"The use of GnRH-agonist trigger for the final maturation of oocytes in normal and low responders undergoing planned oocyte cryopreservation","volume":"35","author":"Maslow","year":"2020","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B94","doi-asserted-by":"crossref","first-page":"101597","DOI":"10.1016\/j.esmoop.2023.101597","article-title":"Long-acting gonadotropin-releasing hormone agonist trigger in fertility preservation cycles before chemotherapy","volume":"8","author":"Massarotti","year":"2023","journal-title":"ESMO Open"},{"key":"2026022403013837700_deag018-B95","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/humrep\/dead038","article-title":"The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF","volume":"38","author":"Massin","year":"2023","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B96","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0015-0282(00)00492-1","article-title":"Distinction between early and late ovarian hyperstimulation syndrome","volume":"73","author":"Mathur","year":"2000","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B97","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.fertnstert.2009.05.005","article-title":"A prospective, randomized, controlled trial comparing three different gonadotropin regimens in oocyte donors: ovarian response, in vitro fertilization outcome, and analysis of cost minimization","volume":"94","author":"Melo","year":"2010","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B98","first-page":"Cd005070","article-title":"Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF\/ICSI cycles","volume":"5","author":"Mochtar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B99","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12958-021-00741-0","article-title":"The effect of Myo-inositol on fertility rates in poor ovarian responder in women undergoing assisted reproductive technique: a randomized clinical trial","volume":"19","author":"Mohammadi","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"key":"2026022403013837700_deag018-B100","doi-asserted-by":"crossref","first-page":"hoaa066","DOI":"10.1093\/hropen\/hoaa066","article-title":"Fresh and cumulative live birth rates in mild versus conventional stimulation for IVF cycles in poor ovarian responders: a systematic review and meta-analysis","volume":"2021","author":"Montoya-Botero","year":"2021","journal-title":"Hum Reprod Open"},{"key":"2026022403013837700_deag018-B101","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.fertnstert.2003.11.031","article-title":"A controlled trial of natural cycle versus microdose gonadotropin-releasing hormone analog flare cycles in poor responders undergoing in vitro fertilization","volume":"81","author":"Morgia","year":"2004","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B102","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/0974-1208.101014","article-title":"Letrozole in a low-cost in vitro fertilization protocol in intracytoplasmic sperm injection cycles for male factor infertility: A randomized controlled trial","volume":"5","author":"Mukherjee","year":"2012","journal-title":"J Hum Reprod Sci"},{"key":"2026022403013837700_deag018-B103","first-page":"Cd009749","article-title":"Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction","volume":"6","author":"Naik","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B104","doi-asserted-by":"crossref","first-page":"101698","DOI":"10.1016\/j.jogoh.2020.101698","article-title":"Effect of myo-inositol supplementation on ICSI outcomes among poor ovarian responder patients: a randomized controlled trial","volume":"49","author":"Nazari","year":"2020","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2026022403013837700_deag018-B105","first-page":"Cd012693","article-title":"Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF\/ICSI)","volume":"1","author":"Ngwenya","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/humupd\/dmr037","article-title":"The poor responder in IVF: is the prognosis always poor?: a systematic review","volume":"18","author":"Oudendijk","year":"2012","journal-title":"Hum Reprod Update"},{"key":"2026022403013837700_deag018-B107","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1093\/humrep\/dex319","article-title":"Individualized versus standard FSH dosing in women starting IVF\/ICSI: an RCT. Part 2: The predicted hyper responder","volume":"32","author":"Oudshoorn","year":"2017","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B108","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/j.fertnstert.2010.04.035","article-title":"Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial","volume":"94","author":"Pacchiarotti","year":"2010","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B109","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.fertnstert.2005.07.1292","article-title":"Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles","volume":"85","author":"Papanikolaou","year":"2006","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B110","first-page":"57","article-title":"The effect of four different gonadotropin protocols on oocyte and embryo quality and pregnancy outcomes in IVF\/ICSI cycles; a randomized controlled trial","volume":"42","author":"Parsanezhad","year":"2017","journal-title":"Iran J Med Sci"},{"key":"2026022403013837700_deag018-B111","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.rbmo.2017.06.002","article-title":"Random-start ovarian stimulation in women desiring elective cryopreservation of oocytes","volume":"35","author":"Pereira","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2026022403013837700_deag018-B112","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/humrep\/dez132","article-title":"Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation","volume":"34","author":"Popovic-Todorovic","year":"2019","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B113","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.fertnstert.2016.04.006","article-title":"Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection","volume":"106","author":"Qin","year":"2016","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B114","doi-asserted-by":"crossref","first-page":"102139","DOI":"10.1016\/j.jogoh.2021.102139","article-title":"Effects of using letrozole in combination with the GnRH antagonist protocol for patients with poor ovarian response: a meta-analysis","volume":"50","author":"Qin","year":"2021","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2026022403013837700_deag018-B115","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10815-020-01742-5","article-title":"A prospective randomized trial comparing corifollitropin-\u03b1 late-start (day 4) versus standard administration (day 2) in expected poor, normal, and high responders undergoing controlled ovarian stimulation for IVF","volume":"37","author":"Revelli","year":"2020","journal-title":"J Assist Reprod Genet"},{"key":"2026022403013837700_deag018-B116","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/humrep\/dex027","article-title":"The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review","volume":"32","author":"Rodgers","year":"2017","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B117","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0015-0282(98)00018-1","article-title":"Recruitment of follicles by recombinant human follicle-stimulating hormone commencing in the luteal phase of the ovarian cycle","volume":"69","author":"Rombauts","year":"1998","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B118","first-page":"135","article-title":"Comparison in vitro fertilization outcomes between DouStim and minimal stimulation protocols in poor ovarian responders: a randomized clinical trial","volume":"18","author":"Saharkhiz","year":"2024","journal-title":"Int J Fertil Steril"},{"key":"2026022403013837700_deag018-B119","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1093\/humrep\/deaa226","article-title":"The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF\/ICSI for high responders: a randomized controlled trial","volume":"35","author":"Santos-Ribeiro","year":"2020","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B120","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.fertnstert.2006.02.110","article-title":"Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial","volume":"86","author":"Serafini","year":"2006","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B121","first-page":"643","article-title":"Myo-inositol effect on pregnancy outcomes in infertile women undergoing in vitro fertilization\/intracytoplasmic sperm injection: A double-blind RCT","volume":"20","author":"Seyedoshohadaei","year":"2022","journal-title":"Int J Reprod Biomed"},{"key":"2026022403013837700_deag018-B122","first-page":"99","article-title":"Does triggering ovulation by 5000 IU of uhCG affect ICSI outcome?","volume":"11","author":"Shaltout","year":"2006","journal-title":"Middle East Fertil Soc J"},{"key":"2026022403013837700_deag018-B123","first-page":"CD012378","article-title":"Inositol for subfertile women with polycystic ovary syndrome","volume":"2018","author":"Showell","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B124","doi-asserted-by":"crossref","first-page":"146","DOI":"10.21037\/atm.2019.04.16","article-title":"Clinical outcomes following long GnRHa ovarian stimulation with highly purified human menopausal gonadotropin plus rFSH or rFSH in patients undergoing in vitro fertilization-embryo transfer: a multi-center randomized controlled trial","volume":"7","author":"Shu","year":"2019","journal-title":"Ann Transl Med"},{"key":"2026022403013837700_deag018-B125","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s43032-021-00683-3","article-title":"A randomized controlled trial on the efficacy and safety of low-dose hCG in a short protocol with GnRH agonist and ovarian stimulation with recombinant FSH (rFSH) during the follicular phase in infertile women undergoing ART","volume":"29","author":"Siristatidis","year":"2022","journal-title":"Reprod Sci"},{"key":"2026022403013837700_deag018-B126","first-page":"CD004832","article-title":"Aspirin for in vitro fertilisation","volume":"11","author":"Siristatidis","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B127","first-page":"Cd006919","article-title":"Gonadotropin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction","volume":"1","author":"Siristatidis","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B128","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/oxfordjournals.humrep.a019508","article-title":"A randomized comparative study of highly purified follicle stimulating hormone and human menopausal gonadotrophin for ovarian hyperstimulation in an oocyte donation programme","volume":"11","author":"S\u00f6derstr\u00f6m-Anttila","year":"1996","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B129","doi-asserted-by":"crossref","first-page":"103337","DOI":"10.1016\/j.rbmo.2023.103337","article-title":"Random start ovarian stimulation before gonadotoxic therapies in women with cancer: a systematic review and meta-analysis","volume":"47","author":"S\u00f6nmezer","year":"2023","journal-title":"Reprod Biomed Online"},{"key":"2026022403013837700_deag018-B130","first-page":"CD000099","article-title":"Growth hormone for in vitro fertilisation (IVF)","volume":"11","author":"Sood","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B131","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.fertnstert.2013.12.026","article-title":"Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles","volume":"101","author":"Steward","year":"2014","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B132","doi-asserted-by":"crossref","first-page":"13835","DOI":"10.1038\/s41598-018-32128-4","article-title":"Elevated basal luteinizing hormone does not impair the outcome of human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles","volume":"8","author":"Sun","year":"2018","journal-title":"Sci Rep"},{"key":"2026022403013837700_deag018-B133","first-page":"344","article-title":"Conventional follicular-phase ovarian stimulation vs. luteal-phase stimulation in suboptimal responders: a randomized controlled trial","volume":"4","author":"Su\u00f1ol","year":"2023","journal-title":"F S Rep"},{"key":"2026022403013837700_deag018-B134","first-page":"Cd008605","article-title":"Dopamine agonists for preventing ovarian hyperstimulation syndrome","volume":"4","author":"Tang","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B135","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.fertnstert.2017.04.014","article-title":"Reproductive outcomes after a single dose of gonadotropin-releasing hormone agonist compared with human chorionic gonadotropin for the induction of final oocyte maturation in hyper-responder women aged 35\u201340 years","volume":"107","author":"Tannus","year":"2017","journal-title":"Fertil Steril"},{"key":"2026022403013837700_deag018-B136","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejogrb.2018.10.034","article-title":"Ovarian stimulation with corifollitropin alfa followed by hp-hMG compared to hp-hMG in patients at risk of poor ovarian response undergoing ICSI: a randomized controlled trial","volume":"231","author":"Taronger","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2026022403013837700_deag018-B137","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1093\/humrep\/17.12.3129","article-title":"Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence","volume":"17","author":"Tesarik","year":"2002","journal-title":"Human Reproduction (Oxford, England)"},{"key":"2026022403013837700_deag018-B138","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1093\/humrep\/des256","article-title":"A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization","volume":"27","author":"Thuesen","year":"2012","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B139","doi-asserted-by":"crossref","first-page":"101643","DOI":"10.1016\/j.jogoh.2019.101643","article-title":"The role of Letrozole (LE) in controlled ovarian stimulation (COS) in patients at high risk to develop ovarian hyper stimulation syndrome (OHSS). A prospective randomized controlled pilot study","volume":"49","author":"Tshzmachyan","year":"2020","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2026022403013837700_deag018-B140","first-page":"CD006105","article-title":"Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome","volume":"12","author":"Tso","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B141","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejogrb.2023.12.035","article-title":"Oocyte competence is comparable between progestin primed ovarian stimulation with Norethisterone acetate (NETA-PPOS) and GnRH-antagonist protocols: A matched case-control study in PGT-A cycles","volume":"294","author":"Vaiarelli","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2026022403013837700_deag018-B142","first-page":"CD009154","article-title":"Luteal phase support for assisted reproduction cycles","volume":"2015","author":"van der Linden","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B143","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/oxfordjournals.humrep.a138053","article-title":"Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study","volume":"8","author":"van Hooff","year":"1993","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B144","first-page":"CD005354","article-title":"Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles","volume":"2011","author":"van Wely","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B145","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/humupd\/dmt014","article-title":"Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles","volume":"19","author":"Venetis","year":"2013","journal-title":"Hum Reprod Update"},{"key":"2026022403013837700_deag018-B146","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/humupd\/dmac040","article-title":"What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis","volume":"29","author":"Venetis","year":"2023","journal-title":"Hum Reprod Update"},{"key":"2026022403013837700_deag018-B147","author":"Vermeulen","year":"2020"},{"key":"2026022403013837700_deag018-B148","article-title":"Does serum LH level influence IVF outcomes in women with PCOS undergoing GnRH-antagonist stimulation: a novel indicator","volume":"11","author":"Wang","year":"2022","journal-title":"J Clin Med"},{"key":"2026022403013837700_deag018-B149","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00404-023-07285-1","article-title":"Effect of GnRH agonist trigger with or without low-dose hCG on reproductive outcomes for PCOS women with freeze-all strategy: a propensity score matching study","volume":"309","author":"Wang","year":"2024","journal-title":"Arch Gynecol Obstet"},{"key":"2026022403013837700_deag018-B150","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/oxfordjournals.humrep.a019357","article-title":"The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women","volume":"11","author":"Westergaard","year":"1996","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B151","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/09513590.2011.633666","article-title":"Monitoring stimulated cycles during in vitro fertilization treatment with ultrasound only\u2014preliminary results","volume":"28","author":"Wiser","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"2026022403013837700_deag018-B152","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/humrep\/deae145","article-title":"A modified flexible GnRH antagonist protocol using antagonist early cessation and a gonadotropin step-down approach improves live birth rates in fresh cycles: a randomized controlled trial","volume":"39","author":"Xu","year":"2024","journal-title":"Hum Reprod"},{"key":"2026022403013837700_deag018-B153","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12958-019-0483-x","article-title":"Letrozole supplementation during controlled ovarian stimulation in expected high responders: a pilot randomized controlled study","volume":"17","author":"Yang","year":"2019","journal-title":"Reprod Biol Endocrinol"},{"key":"2026022403013837700_deag018-B154","doi-asserted-by":"crossref","first-page":"e12543","DOI":"10.1002\/rmb2.12543","article-title":"The effectiveness of controlled ovarian stimulation with tamoxifen for patients with estrogen-sensitive breast cancer: a systematic review and meta-analysis","volume":"22","author":"Yoshida","year":"2023","journal-title":"Reprod Med Biol"},{"key":"2026022403013837700_deag018-B155","first-page":"CD003719","article-title":"Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles","volume":"4","author":"Youssef","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B156","first-page":"CD008046","article-title":"Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology","volume":"2014","author":"Youssef","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B157","first-page":"CD011184","article-title":"Fresh versus frozen embryo transfers in assisted reproduction","volume":"2","author":"Zaat","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022403013837700_deag018-B158","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/humrep\/dex234","article-title":"The International Glossary on Infertility and Fertility Care, 2017","volume":"32","author":"Zegers-Hochschild","year":"2017","journal-title":"Hum Reprod)"},{"key":"2026022403013837700_deag018-B159","first-page":"CD011184","article-title":"Impact of luteinizing hormone on IVF\/ICSI assisted reproduction on the initiation day of gonadotropin-releasing hormone antagonist protocol","volume":"2","author":"Zhang","year":"2024","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"2026022403013837700_deag018-B160","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12958-022-00888-4","article-title":"Is it necessary to monitor the serum luteinizing hormone (LH) concentration on the human chorionic gonadotropin (HCG) day among young women during the follicular-phase long protocol? A retrospective cohort study","volume":"20","author":"Zhang","year":"2022","journal-title":"Reprod Biol Endocrinol"},{"key":"2026022403013837700_deag018-B161","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12958-021-00836-8","article-title":"Evaluation of GnRH antagonist pretreatment before ovarian stimulation in a GnRH antagonist protocol in normal ovulatory women undergoing IVF\/ICSI: a randomized controlled trial","volume":"19","author":"Zhang","year":"2021","journal-title":"Reprod Biol Endocrinol"},{"key":"2026022403013837700_deag018-B162","doi-asserted-by":"crossref","first-page":"1191827","DOI":"10.3389\/fendo.2023.1191827","article-title":"Association between serum LH levels on hCG trigger day and live birth rate after fresh embryo transfer with GnRH antagonist regimen in different populations","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026022403013837700_deag018-B163","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1515\/med-2022-0594","article-title":"Estradiol pretreatment in GnRH antagonist protocol for IVF\/ICSI treatment","volume":"17","author":"Zhu","year":"2022","journal-title":"Open Med"},{"key":"2026022403013837700_deag018-B164","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3389\/fendo.2019.00875","article-title":"Randomized, controlled pilot study of low-dose human chorionic gonadotropin administration beginning from the early follicular phase for women with polycystic ovarian syndrome undergoing ovarian stimulation using the progesterone protocol","volume":"10","author":"Zhu","year":"2019","journal-title":"Front Endocrinol"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/advance-article-pdf\/doi\/10.1093\/humrep\/deag018\/67084169\/deag018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/advance-article-pdf\/doi\/10.1093\/humrep\/deag018\/67084169\/deag018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:02:05Z","timestamp":1771920125000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/advance-article\/doi\/10.1093\/humrep\/deag018\/8495097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":164,"URL":"https:\/\/doi.org\/10.1093\/humrep\/deag018","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"deag018"}}